Cadrenal Therapeutics, Inc. (CVKD) analyst actions
Rating and price-target actions on CVKD in the public-source dataset. Wires and filings carry few rating actions, so this list is sparse by nature — the hub's by-event-type table holds the measured analyst base rates. Back to the CVKD overview →
2 measured CVKD analyst action events.
| Date | Headline | Event | 5-min | To close |
|---|---|---|---|---|
| Cadrenal Therapeutics Announces Clinical Trial Initiation Plans for Tecarfarin in Patients with End-Stage Kidney Disease (ESKD) Transitioning to Dialysis | Press release | +4.10% | +13.54% | |
| Noble Capital Markets Initiates Coverage on Cadrenal Therapeutics with Outperform Rating and US$4.00 Price Target | Press release | -8.34% | -2.78% |
Keep exploring
More CVKD: earnings → · SEC filings → · CVKD overview →